10-Q – Page 150 – China Stock Advice

CLNT [Cleantech Solutions International,] 10-Q: FORM 10-Q (Mark One) x For the quarterly

[FORM 10-Q (Mark One) x For the quarterly period ended June 30, 2012 o For the transition period from __________ to __________ CLEANTECH SOLUTIONS INTERNATIONAL, NEVADA 90-0648920 (State or other jurisdiction oforporation of organization) (I.R.S. Employer Identification No.) No. 9 Yanyu Middle Road Qianzhou Township, Huishan District, Wuxi City] [SARBANES-OXLEY ACT OF 2002 I, Jianhua Wu, certify that: 1. 2. 3. 4. a) b) designed such internalntrol over financial reporting, orused such internalntrol over financial reporting to be designed under our supervision, to provide reasonablesurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally] [CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICERRBANES-OXLEY ACT OF 2002 I, Wanfen Xu, certify that: 1. 2. 3. 4. a) b) designed such internalntrol over financial reporting, orused such internalntrol over financial reporting to be designed under our supervision, to provide reasonablesurance regarding the reliability of financial reporting and the preparation of financial statements for] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany. Jianhua Wu, Chief Executive Officer Wanfen Xu, Chief Financial Officer (Principal Accounting Officer SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER]

By info| 2016-02-13T13:47:34+00:00 August 14th, 2012|Categories: Chinese Stocks, CLNT, Webplus ver|Tags: 0000819926, 10-Q, 2012-08-14, 3550, CLNT, SPECIAL INDUSTRY MACHINERY (NO METALWORKING MACHINERY)|0 Comments

CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2012 President and Chief Executive Officer EX-32.1 4 cphi10qex321063012.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2012 (principal financial officer and principal accounting officer) EX-32.2 5 cphi10qex322063012.htm]

By info| 2016-03-03T17:42:08+00:00 August 14th, 2012|Categories: Chinese Stocks, CPHI, SEC Original|Tags: 0001106644, 10-Q, 2012-08-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x June 30, 2012

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2012 President and Chief Executive Officer EX-32.1 4 cphi10qex321063012.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2012 (principal financial officer and principal accounting officer) EX-32.2 5 cphi10qex322063012.htm]

By info| 2016-03-03T17:43:09+00:00 August 14th, 2012|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: 0001106644, 10-Q, 2012-08-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]

By info| 2016-03-03T11:52:28+00:00 August 14th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 10-Q, 2012-08-14, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: (Original Filing)

[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Weibing Lu, Chief Executive Officer] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Bing Mei, Chief Financial Officer]

By info| 2016-03-01T04:35:33+00:00 August 14th, 2012|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 10-Q, 2012-08-14, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x June 30, 2012

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]

By info| 2016-03-03T11:53:19+00:00 August 14th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 10-Q, 2012-08-14, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q:

[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Weibing Lu, Chief Executive Officer] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Bing Mei, Chief Financial Officer]

By info| 2016-03-01T04:36:37+00:00 August 14th, 2012|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 10-Q, 2012-08-14, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

CLNT [Cleantech Solutions International,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x For the quarterly period ended June 30, 2012 o For the transition period from __________ to __________ CLEANTECH SOLUTIONS INTERNATIONAL, NEVADA 90-0648920 (State or other jurisdiction oforporation of organization) (I.R.S. Employer Identification No.) No. 9 Yanyu Middle Road Qianzhou Township, Huishan District, Wuxi City] [SARBANES-OXLEY ACT OF 2002 I, Jianhua Wu, certify that: 1. 2. 3. 4. a) b) designed such internalntrol over financial reporting, orused such internalntrol over financial reporting to be designed under our supervision, to provide reasonablesurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally] [CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICERRBANES-OXLEY ACT OF 2002 I, Wanfen Xu, certify that: 1. 2. 3. 4. a) b) designed such internalntrol over financial reporting, orused such internalntrol over financial reporting to be designed under our supervision, to provide reasonablesurance regarding the reliability of financial reporting and the preparation of financial statements for] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany. Jianhua Wu, Chief Executive Officer Wanfen Xu, Chief Financial Officer (Principal Accounting Officer SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER]

By info| 2016-02-02T23:25:42+00:00 August 14th, 2012|Categories: Chinese Stocks, CLNT, SEC Original|Tags: 0000819926, 10-Q, 2012-08-14, 3550, CLNT, SPECIAL INDUSTRY MACHINERY (NO METALWORKING MACHINERY)|0 Comments

CLNT [Cleantech Solutions International,] 10-Q: FORM 10-Q (Mark One) x For the quarterly

[FORM 10-Q (Mark One) x For the quarterly period ended June 30, 2012 o For the transition period from __________ to __________ CLEANTECH SOLUTIONS INTERNATIONAL, NEVADA 90-0648920 (State or other jurisdiction oforporation of organization) (I.R.S. Employer Identification No.) No. 9 Yanyu Middle Road Qianzhou Township, Huishan District, Wuxi City] [SARBANES-OXLEY ACT OF 2002 I, Jianhua Wu, certify that: 1. 2. 3. 4. a) b) designed such internalntrol over financial reporting, orused such internalntrol over financial reporting to be designed under our supervision, to provide reasonablesurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally] [CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICERRBANES-OXLEY ACT OF 2002 I, Wanfen Xu, certify that: 1. 2. 3. 4. a) b) designed such internalntrol over financial reporting, orused such internalntrol over financial reporting to be designed under our supervision, to provide reasonablesurance regarding the reliability of financial reporting and the preparation of financial statements for] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany. Jianhua Wu, Chief Executive Officer Wanfen Xu, Chief Financial Officer (Principal Accounting Officer SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER]

By info| 2016-02-02T23:26:09+00:00 August 14th, 2012|Categories: Chinese Stocks, CLNT, Webplus ver|Tags: 0000819926, 10-Q, 2012-08-14, 3550, CLNT, SPECIAL INDUSTRY MACHINERY (NO METALWORKING MACHINERY)|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x June 30, 2012

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 5 EX-32.2]

By info| 2016-02-07T15:45:38+00:00 August 14th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 10-Q, 2012-08-14, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments